A GP guide to SGLT2 inhibitors in type 2 diabetes
The benefits and adverse effects of this new class of medications
Diabetes affects approximately 1.2 million Australians, with type 2 diabetes accounting for up to 90% of cases.1-3
The risk of adverse kidney outcomes in patients with type 2 diabetes remains high.
The proportion of people starting renal replacement therapy (dialysis or transplant) because of diabetes has increased from 22% to 38% in the past 10 years, and 20% of the burden of all stages of chronic kidney disease (CKD) in Australia is due to diabetes.4
ACEIs or ARBs are renoprotective and are recommended for patients with type 2 diabetes who have or are at high risk of developing kidney disease.5
